Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
2006

Continued Trastuzumab Treatment in Advanced Breast Cancer

Sample size: 54 publication Evidence: moderate

Author Information

Author(s): Bartsch Rupert, Wenzel Catharina, Hussian Dagmar, Pluschnig Ursula, Sevelda Ursula, Koestler Wolfgang, Altorjai Gabriela, Locker Gottfried J, Mader Robert, Zielinski Christoph C, Steger Guenther G

Primary Institution: Medical University of Vienna

Hypothesis

Should trastuzumab treatment continue after the failure of one earlier combination in advanced breast cancer?

Conclusion

Patients benefit from continued trastuzumab treatment even after disease progression.

Supporting Evidence

  • Median time to progression was 6 months across all treatment lines.
  • Response rates decreased from 42.6% in first line to 28.3% beyond second line.
  • 85.2% of patients experienced clinical benefit from first line treatment.

Takeaway

This study shows that some patients with advanced breast cancer can keep taking trastuzumab even if their cancer gets worse, and it can still help them.

Methodology

The study followed 54 patients with HER2-positive advanced breast cancer who continued trastuzumab treatment after previous therapy failure, analyzing time to tumor progression and response rates.

Potential Biases

Potential bias due to the observational nature of the study.

Limitations

The study is limited by the relatively small number of patients included.

Participant Demographics

Median age was 46 years, with a range of 25 to 73 years; 53 were female and 1 male.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI 5.32 – 6.68

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-6-63

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication